News
LUCD
0.9677
+0.29%
0.0028
Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group
TipRanks · 1d ago
Press Release: PAVmed Provides Business Update -2-
Dow Jones · 1d ago
Analysts’ Top Healthcare Picks: Lucid Diagnostics (LUCD), Takeda Pharmaceutical Company (TAK)
TipRanks · 2d ago
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript
Benzinga · 2d ago
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 2d ago
Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision
TipRanks · 2d ago
Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M
Seeking Alpha · 2d ago
*Lucid Diagnostics 2Q Rev $1.5M >LUCD
Dow Jones · 2d ago
Press Release: Lucid Diagnostics Provides -2-
Dow Jones · 2d ago
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at LUCD last week (0803-0807)?
Weekly Report · 5d ago
Lucid announces Concert issued positive coverage policy for EsoGuard test
TipRanks · 08/05 14:06
Weekly Report: what happened at LUCD last week (0727-0731)?
Weekly Report · 08/03 09:31
Weekly Report: what happened at LUCD last week (0720-0724)?
Weekly Report · 07/27 09:33
Weekly Report: what happened at LUCD last week (0713-0717)?
Weekly Report · 07/20 09:31
Weekly Report: what happened at LUCD last week (0706-0710)?
Weekly Report · 07/13 09:32
Weekly Report: what happened at LUCD last week (0629-0703)?
Weekly Report · 07/06 09:34
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection
Seeking Alpha · 07/03 14:03
Weekly Report: what happened at LUCD last week (0622-0626)?
Weekly Report · 06/29 09:31
Lucid Diagnostics Shareholders Approve Stock Authorization Increase
TipRanks · 06/24 21:32
More
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.